Pharmaceutical drug molecules are becoming increasingly complex, posing challenges in formulation development and manufacturing. This is particularly true of small molecule drug APIs and peptides, both of which have a…
Coronavirus has impacted drug supply chains. At first blush, people will likely read that sentence to mean drugs aren’t arriving at their intended destination. That precursor chemicals, intermediaries, APIs, or…
There were many remarkable moments during this year’s World Cup – but the Japanese and Senegal teams and their fans really stand out for non-football-related reasons. They gained global admiration…
Synthetic route selection is a crucial element in API manufacturing. While the requirements of the synthetic process of a drug will naturally evolve during its life cycle, scouting alternate routes…
I recently came across two interesting articles in recent issues of Contract Pharma. One was their annual outsourcing survey, which I find often dovetails with our experiences at Neuland. The…
A couple of years ago, I published a post on 5 API Regulatory Challenges to Avoid, and it was interesting to look over the list and contemplate what updates I’d…
I’ve been trying to get caught up on some reading this month, and thought I’d put together a roundup of interesting articles I’ve run across recently. Grading GDUFA, at Contract…
There’s an article on Piramal’s Pharma Solutions division at PharmTech about how they are encouraging pharma companies to implement green chemistry earlier in the drug development cycle. Yes, we agree…
7 ways to boost profits and reduce pharma synthesis waste At Neuland, we’re advocates of green chemistry. Not only is it better for the environment, but it’s also just logistically…
The Right Route Can Deliver Fewer Steps, More Consistent Batches, Cleaner Processes…and Cost Savings With drug development and manufacturing processes becoming more complex, alternate synthetic route design is often a…
